DGAP-Adhoc

Biotest AG: Biotest AG sets the subscription price and the offer price for the new preferred shares at EUR 52.00 per preferred share

Biotest AG / Key word(s): Capital Increase

10.06.2013 19:05

Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

/
Ad-hoc RELEASE
Announcement according to § 15 Sec. 1 Securities Trading Act (WpHG)

Biotest AG sets the subscription price and the offer price for the new
preferred shares at EUR 52.00 per preferred share

Dreieich, 10 June 2013 - The management board of Biotest AG decided today,
in consultation with equinet Bank AG, on the further parameters for the
capital increase against cash contribution announced on 10 June 2013. The
subscription price for the new preferred shares to be offered to existing
shareholders in the subscription offer and the offer price for the new
preferred shares offered by means of the Pre-placement to qualified
investors in Germany and in other European countries has been set at EUR
52.00 per preferred share.

Up to 1,461,909 new no-par value preferred bearer shares (shares without
nominal value) will be issued representing a notional interest of EUR 2.56
in Biotest AG and carrying full dividend rights from 1 January 2013 ('New
Shares').

All 1,461,909 New Shares have been placed pursuant to the Pre-placement.
Ca. 59 % of the New Shares allocated for investors in the Pre-Placement
will be subject to a claw-back in case of an exercise of subscription
rights by those existing shareholders which have not transferred their
subscription rights to equinet Bank AG.

The subscription period is expected to begin on 12 June and end on 25 June
2013 (inclusive). The delivery of the New Shares is expected to take place
on 1 July 2013.

The gross proceeds of the Company will amount to approximately EUR 76.0
million.

Biotest Aktiengesellschaft
The Management Board
Biotest AG
Landsteinerstr. 5
63303 Dreieich
www.biotest.de

ISIN: DE0005227235; DE0005227201
WKN: 522723; 522720

This publication constitutes neither an offer to sell nor a solicitation to
buy or subscribe to securities. The subscription offer as a public offering
in Germany and Luxembourg will be made solely on the basis of the
securities prospectus dated 10 June 2013 as approved by the Bundesanstalt
für Finanzdienstleistungsaufsicht (BaFin). The information legally required
to be provided to investors is contained only in the securities prospectus.
The securities prospectus is available free of charge on the internet at
the website of the issuer (www.biotest.de) and during normal business hours
at the issuer, on a date to be determined.